Skip to main content

Proteome Sciences Lowers 2014 Guidance, Cites Delay of Contracts

Premium

NEW YORK (Genomeweb News) – Proteome Sciences this week lowered its full year 2014 guidance, citing delays in the timing of several contracts.

The company said that as a result it expects 2014 revenues to be "somewhat lower" than the £2.14 million ($3.35 million) in revenues it posted in 2013.

The company said that it expected the delayed revenues to be captured in 2015, based on strong growth in its biomarker services and TMT reagent businesses.

Proteome Sciences added that it has begun discussions with several parties regarding outlicensing its biomarkers for detection of mild cognitive impairment and Alzheimer's disease.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.